<scp>Long‐term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52‐week</scp> outcomes from the <scp>DEPICT</scp>‐1 and ‐2 studies
Distribution of the number of citations over years.